Skip to content

Disc Medicine IRON Free cash flow yield

Free cash flow yield at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
9.6%-0.9pp
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
3.3%+2.2pp
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
-12.1%-4.1pp
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
-19.4%-3.1pp
Beam Therapeutics logo
Beam TherapeuticsBEAM
-15.8%-2.0pp
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
-25.1%-6.6pp

Other financials

Income statement

See full
Operating income-$69.5M-74.0%
Net income-$63.5M-86.3%
EPS (diluted)-$1.65-61.8%

Balance sheet

See full
Cash & equivalents$88.9M-27.5%
Total debt$31.1M+1.4%
Total equity$688.4M+4.3%
Total assets$750.2M+5.8%

Cash flow

See full
Operating cash flow-$62.2M-50.4%
CapEx--100%
Free cash flow-$62.2M-47.4%

Valuation

See full
Market cap$2.69B+42.2%
Enterprise value$2.63B+46.7%

Returns & leverage

See full
Return on equity-35.8%+41.3pp
Debt / equity0.0×
Current ratio24×-13.6×

Where this comes from

Calculated from Disc Medicine’s reported figures.

Based on trailing twelve months.

The official record: Disc Medicine’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Disc Medicine's free cash flow yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Disc Medicine's free cash flow yield?
Disc Medicine (IRON) reported free cash flow yield of -8.3% in Q1 2026.
How has Disc Medicine's free cash flow yield changed year-over-year?
Disc Medicine's free cash flow yield decreased by 37.5% year-over-year, from -6% to -8.3%.
What is the long-term trend for Disc Medicine's free cash flow yield?
Over 3 years (2022 to 2025), Disc Medicine's free cash flow yield has grown at a -66.5% compound annual growth rate (CAGR), from -160.5% to -6%.
What does free cash flow yield mean?
Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.